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Abstract
Exosomes are microvesicles with sizes ranging from 50 to 150 nm. These small vesicles 
are known to morphologically and functionally resemble virus particles from human 
immunodeficiency virus type I (HIV-I) and human T-lymphotropic virus type I (HTLV-I). 
The function of exosomes is to mainly mediate cell-to-cell communication by exchanging 
various macromolecules including proteins, lipids and nucleic acids in diverse cellular 
processes. Due to its size and structural simplicity, the transfer of pathogenic or virulent 
cellular factors across the cells mediated by exosomes is more efficient, hence facilitating 
the dissemination of viral infections and cancer diseases. The pathogenic role of exo-
somes in various cancers such as lung and breast, and their potentials as biomarkers 
have been previously studied, yet limited information is known for Epstein-Barr virus 
(EBV)-associated cancers. In this chapter, we discuss current evidences that support the 
pathogenic roles of exosomes in EBV-related cancers and their potentials as biomarkers 
in cancer diagnostics and therapy response. Here, we also highlight the potential chal-
lenges in the development of exosome-based biomarkers for clinical application.
Keywords: EBV, exosomes, cancer, biomarker, nasopharyngeal carcinoma, diagnostics, 
therapy
1. Introduction
Exosomes are microvesicles that play major roles in cell-to-cell communication. These small 
vesicles have nano-scaled size, resembling the size of HIV-1 particles. Indeed, several reports 
have highlighted the similarity between exosomes and HIV-1 particles in terms of structure 
and functions [1, 2]. Biological roles of exosomes in HIV-1 pathogenesis have been extensively 
reviewed and the implication of the pathogenic exosomes depends highly on the contents 
that they carry [3, 4]. The functions of exosomes in other viral infections, such as hepatitis 
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C virus (HCV), herpes simplex virus (HSV) and so on, have also been demonstrated [5, 6]. In 
addition to viral diseases, exosomes have also been reported to play critical roles in cancer 
pathogenesis, including those in glioma, lymphoma, colorectal carcinoma, melanoma, ovar-
ian and breast cancers [7, 8]. However, little is known for the function of exosomes derived 
from tumour viruses or oncoviruses such as HTLV-1, EBV and human papilloma viruses 
(HPV) in virus spreading as well as oncovirus-driven tumour development and dissemina-
tion. Among all, EBV is the most common infection and it infects more than 90% of human 
adult population globally [9]. Cumulative findings demonstrated that EBV infection is asso-
ciated with various lymphoid and epithelial malignancies, including nasopharyngeal carci-
noma (NPC), Burkitt’s lymphoma (BL), gastric carcinoma (GC), Hodgkin’s lymphoma (HL) 
and Non-Hodgkin’s lymphoma [9, 10]. Similarly, EBV has also been reported to contribute to 
breast and cervical cancers [11, 12]. Figure 1 summarizes the cancers that are associated with 
EBV infection, and percent association with EBV is depicted in a form of pyramid.
Exosomes are ubiquitously present in almost all biological fluids, including urine, plasma, 
saliva, ascites, breast milk, semen, bronchoalveolar lavage liquid, amniotic fluid and cere-
brospinal fluid [4–7]. They are secreted from various cell types such as dendritic cells (DCs), 
macrophages, T cells, B cells and cancerous cells [4–7]. The omnipresence of exosomes makes 
them the ideal targets for cancer diagnostics and anti-cancer therapy. However, it remains 
to be seen whether exosomes from different sources present similar pathogenic profiles and 
can be interchangeably targeted for diagnostics and therapeutic purposes. Exosomes gener-
ally have a density of 1.13–1.21 g/mL [13]. They are surrounded by a lipid bilayer and they 
are enriched with macromolecules such as lipids (e.g. cholesterol and glycosphingolipids), 
carbohydrates (e.g. high mannose and complex N-linked glycans), proteins (e.g. tetraspanins 
CD9, CD63 and CD81, MHC molecules, Rabs, actin, alix, HSP70 and TSG101) and nucleic 
acids (e.g. DNAs, mRNAs and miRNAs) [14, 15]. While EBV infection is highly associated 
Figure 1. Association of EBV infection with virus-associated cancers. The association of EBV and cancers is represented 
by the above pyramid in a rising order from top to bottom. Almost 100% of undifferentiated NPC cases are associated 
with EBV infection while cervical cancer has been reported to be linked with EBV infection, but to the least extent with 
about less than 5% of total cases.
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with a plethora of cancer diseases, it is strikingly surprising that only a few studies have 
been carried out to investigate the role of EBV-derived exosomes in cancer development and 
progression. This chapter aims to summarize current findings that demonstrate the biological 
functions of EBV-derived exosomes in the cancer pathogenesis. We also attempt to discuss 
the potentials of using EBV-derived exosomes as diagnostic biomarkers and to target these 
exosomes in anti-cancer therapy, while reviewing the challenges entailed in the above efforts.
2. Pathogenic roles of exosomes in EBV-associated cancers
Exosomes are originated from cellular endosomes, whereby the inward budding takes place 
on endosomal multivesicular bodies (MVBs) to form intraluminal vesicles (ILVs) [5, 6]. The 
subsequent molecular event then determines whether ILVs enter lysosomal degradation path-
way or are being secreted out from the producer cells in the form of exosomes upon the fusion 
of MVB membrane with the plasma membrane [5, 6]. Figure 2 illustrates these processes that 
involve the budding of endosomes, formation of EBV pathogenic factors-loaded exosomes 
and the delivery of the pathogenic exosomes to the target cells. The biogenesis of exosomes 
has been previously reviewed in great depth [14, 15], and these findings are important to 
enhance our understandings towards the function of exosomes in multiple cellular processes 
especially in cancer pathogenesis. The role of EBV-derived exosomes in EBV-associated can-
cers has been partly discussed in previous reviews [5, 8], but the proteins or genes involved 
and the underlying mechanisms have not been clearly illustrated. In this section, we will dis-
cuss the pathogenic roles of the contents in EBV-derived exosomes such as latent membrane 
proteins (LMPs), mRNAs and miRNAs in contributing to the EBV-associated cancers.
2.1. Exosomal latent membrane proteins (LMPs)
Latent membrane proteins (LMPs) are oncogenic proteins that are highly associated with can-
cer pathogenesis particularly in HL and NPC. There are two types of LMPs: LMP1, and LMP2 
that consists of LMP2A and LMP2B. Each of these oncogenic proteins has distinct function in 
EBV-related human cancers [16, 17]. For instances, LMP1, which is a viral mimic of tumour 
necrosis factor receptor (TNFR) family member CD40, has been reported to activate a cascade 
of oncogenic signalling pathways such as nuclear factor kappa B (NF-κB), phosphatidylinosi-
tol-4,5-bisphosphate 3-kinase (PI3K) and c-Jun N-terminal kinases (JNKs) in EBV-associated 
cancers [10, 16, 17]. On the other hand, LMP2 plays central roles in maintaining viral latency 
in EBV-infected B cells as well as inducing transformation and migration of EBV-infected 
cells [10, 16, 17]. Whether or not the functions of cell-associated LMPs are fully retained in 
the exosomal LMPs, it remains to be proven. The development of the EBV-related cancers is 
associated with three EBV latency types based on the expression of EBV proteins (i.e. LMP1, 
LMP2 and Epstein-Barr virus nuclear antigen-1, EBNA1). Latency type I, which is usually 
observed in BL and GC, consistently displays strong expression of EBNA1 [17, 18]. Latency 
type II, on the other hand, results in the expression of LMP1, LMP2 and EBNA1 as seen in HL 
and NPC, whereas in latency type III, all latent proteins/antigens are expressed in the course 
of acquired immune deficiency syndrome (AIDS)-related lymphomas and lymphoblastoid 
Exosomes as the Promising Biomarker for Epstein-Barr Virus (EBV)-Associated Cancers
http://dx.doi.org/10.5772/intechopen.69532
99
cell lines (LCLs) [17, 18]. Of note, the LMPs-carrying exosomes have been previously shown 
to be secreted by EBV-infected cells particularly the NPC cells [19–21].
So far, only a few studies have shown the involvement of exosomal LMP1 in activating various 
oncogenic pathways in EBV-associated cancers unlike those in the case of cell-derived LMP1 
[16, 17]. Current findings suggest that exosome-derived LMP-1 plays central roles in attenu-
ating the immune response in both EBV infection and the development and progression of 
EBV cancers [20, 22, 23]. For instances, the LMP1- and galectin 9-containing exosomes derived 
from EBV-infected LCLs and NPC cells have been found to inhibit infiltrating T-lymphocyte 
activation and proliferation through an action mediated by the conserved trans-membrane 
domain of LMP1 [20]. This consequently resulted in the immune escape of tumour cells, and 
hence promoting the cancer growth and progression [24]. Exosomes containing LMP1 and 
HIFα have also been demonstrated to induce tumour invasion in NPC [19]. Moreover, LMP1 
Figure 2. Generation of exosomes in EBV-infected cells and delivery of EBV pathogenic factors-enriched exosomes to 
recipient cells. (a) EBV infects B cells through viral glycoproteins/CD21 interaction, whereas EBV could infect epithelial 
cells either through cell-free manner or cell-to-cell contact mediated by infected B cells. (b) Exosomes are generated 
from the inward budding of endosomes, which then forms MVBs followed by ILVs. (c) ILVs are then either degraded 
by lysosomes or released from the producer cells extracellularly as exosomes. (d) Owing to the overexpression of EBV 
proteins/genes in the infected cell, exosomes are loaded with these pathogenic factors. (e) These exosomes are then 
delivered to the neighbouring cells via phagocytosis, receptor- or caveolin-mediated endocytosis. (f) The pathogenic 
factors are released from the EBV-derived exosomes, which then contribute to the cancer pathogenesis.
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was shown to promote the expression of fibroblasts growth factor 2 (FGF2) and along with the 
LMP1, FGF2 was excreted from the tumour cells via Na(+)/K(+)-ATPase-dependent exosomal 
pathway [25]. Notably, FGF2 is an important angiogenic factor in tumour invasion and it has 
been recently shown that FGF2 can be targeted by miR-16 to inhibit in cell proliferation and 
invasion in NPC [26]. However, whether or not the LMP1-induced exosome-derived FGF2 
secretion is implicated in the EBV-associated cancers, particularly in the aspect of tumour 
metastasis warrants further investigations.
On top of the immunosuppressive and potentially invasive roles of exosomal LMP1, expres-
sion of intercellular adhesion molecule 1 (ICAM1) or CD54 was also up-regulated by exosomal 
LMP1 [21]. Notably, overexpression of ICAM1 is generally seen in various types of EBV-related 
cancers such as NPC, GC and NHL [27–29]. Similarly, exosomal LMP1 also induced epidermal 
growth factor receptor (EGFR) expression [30] which is another important receptor that modu-
lates a cascade of oncogenic signalling pathways such as mitogen-activated protein kinase 
(MAPK), c-Jun N terminal kinase (JNK), phosphatidylinositol 3 kinase (PI3K) and nuclear 
factor kappa-beta (NF-κB) in EBV cancers [31, 32]. In line with of the role of exosomal LMP1 
in EGFR-related pathways, Meckes and co-workers also demonstrated that exosomal LMP1 
activated Extracellular signal-regulated kinase (ERK) and v-Akt murine thymoma viral onco-
gene homolog (AKT) signalling pathways in the target cells [30]. This finding suggests that the 
transfer of oncogenic LMP1 via exosomal pathway may modulate the growth of neighbouring 
cells, hence contributing to the cellular transformation of cancer cells.
Interestingly, exosomal LMP1 is also found to interact with tetraspanin CD63, a common 
marker of exosomes. This interaction facilitates the former to escape lysosomal degradation 
[33] which may result in enhanced oncogenicity of exosomal LMP1. In addition, the level of 
LMP1 is highly correlated with CD63 expression [19]. This suggests that LMP1 may upregu-
late the exosomal secretion, hence promoting the EBV-associated cancers [19]. As summa-
rized in Table 1, cumulative findings suggest that exosomal LMP1 promotes the growth and 
progression of EBV-associated cancers. While the cell-associated or intracellular LMP1 plays 
multiple roles in EBV latent infection and cancer pathogenesis particularly by modulating 
NF-κB, PI3K/AKT, MAPK and JAK/STAT pathways [31, 32], future investigations are war-
ranted to demonstrate whether the exosomal LMP1 similarly carries these tumorigenic func-
tions and pathogenic effects in EBV-associated cancers.
As compared with LMP1, the role and function of exosomal LMP2A/2B in EBV-associated 
cancers are less understood. Incorporation of LMP2 into exosomes has been previously 
observed and these exosomes were released and taken by recipient cells [34, 35–37]. Several 
studies have provided insights on the mechanism of exosomal LMP2 secretion. Ikeda and 
Longnecker demonstrated that cholesterol depletion via methyl-beta-cyclodextrin (MCD) 
depletion can increase exosomal secretion of LMP2A, indicating the inverse dependency 
between the release of LMP2A-carrying exosomes and cholesterol level [35]. In another study, 
the interaction between LMP2A and endocytic adapter proteins, Amphiphysin 1 and 2 was 
found to be essential in order for LMP2A to accumulate into exosomes [38]. However, no 
further study has been done to investigate the pathogenic role of Amphiphysin proteins on 
EBV-associated cancers. Future investigations are required to uncover the pathogenic role of 
exosomal LMP2 in these cancers.
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2.2. Exosomal RNAs
Cancer-derived exosomes carry RNAs particularly miRNAs that are implicated in cancer 
pathogenesis such as in breast and colorectal cancers [39, 40]. In EBV-related cancers, the 
pathogenic role of RNAs such as miRNAs, mRNAs and Epstein-Barr virus-encoded small 
RNAs (EBERs) has drawn considerable attention in the past few years [17, 41]. miRNAs are 
non-coding RNAs that modulate multiple cellular processes, including the promotion of 
tumourigenesis via a cascade of signalling pathways [41]. They are small molecules with an 
approximate size of 22 nucleotides [41]. The mature miRNA functions by interacting with the 
target mRNA and block their activities by repressing the translation. The effects of miRNAs 
have been implicated in various EBV-associated cancers such as NPC, GC and BL [17, 41, 42]. 
However, the tumorigenic role of exosomal miRNAs is underexplored in EBV-related cancers 
as opposed to the cellular miRNAs.
Exosomal content Pathogenic effect Reference
LMP1 & HIF1α Promotion of tumour invasion [19]
LMP1 & Galectin 9 Immunosuppression of T lymphocytes [20]
LMP1 & ICAM1 Induction of ICAM1 expression by LMP1
Modulation of multiple oncogenic pathways
[21]
LMP1 & FGF2 Induction of FGF2 expression by LMP1
Potential driver of tumour invasion
[25]
LMP1 & EGFR Induction of EGFR expression by LMP1
Modulation of multiple oncogenic pathways
[30]
LMP1 & CD63 Increased secretion of exosomal LMP1 [33]
LMP2A & Amphiphysin Increased secretion of exosomal LMP2A [38]
BHRF1-3 miRNA Detected in the EBV-infected cells and transferable via exosomes [43]
miR-BART15-3p Detected in EBV-infected cells and transferable via exosomes to 
corresponding cells
[44]
hsa-miR-24-3p
hsa-miR-891p
hsa-miR-106a-5p
hsa-miR-20a-5p
hsa-miR-1908
Inhibition of T-cell proliferation and differentiation
Induction of Treg cells
Increased pro-inflammatory cytokine expression
Regulation of MARK1 signaling pathway
[45]
EBV latent phase mRNAs Potential expression of LMP1, LMP2, EBNA1, and EBNA2 in recipient 
cells upon taking up these exosomes
[46]
EBER1 and EBER2 Detected in the EBV-infected cells and transferable via exosomes [47]
CCL20 Enhanced Treg recruitment and expansion [22]
dUTPase Induction of NK-κB activation and pro-inflammatory cytokine 
secretion
[48]
IFI16, caspase-1, IL-1β, 
IL-18, IL-33
Enrichment of caspase-1 resulted in the secretion of active immune-
modulatory cytokines
[49]
Table 1. Potential pathogenic roles of exosomes in EBV-associated cancers.
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There are substantial findings supporting the notion that oncogenic miRNA-carrying exo-
somes may play pathogenic roles in EBV-associated cancers [21, 30, 43]. For instances, BHRF1-3 
miRNA has been shown to be secreted from the EBV-infected cells and they retained their 
cellular function upon delivery to the recipient cells [43]. Choi and colleagues demonstrated 
that the miR-BART15-3p could be detected in EBV-associated exosomes and its expression 
level was 2 to 16-fold higher in the exosomes compared with the cellular level in GC cells [44], 
hence suggesting its potential tumorigenic role. On the other hand, Ye and group showed 
that the exosomal miRNAs promoted the tumour progression by modulating multiple cel-
lular processes in NPC [45] (Table 1). Further studies are required to investigate and validate 
their roles in promoting EBV-derived cancers. The occurrence of exosomes carrying mRNAs 
encoding for oncogenic EBV proteins such as LMP1, LMP2, EBNA1 and EBNA2 [46, 47] as 
well as EBERs has also been documented (Figure 1). While the functions of these RNAs in the 
EBV-infected cancer cells are well-described, whether or not the exosomal RNAs are transfer-
able to the recipient cells and exert their tumorigenic effects remains a question.
2.3. Other exosomal pathogenic factors
In addition to EBV-associated proteins/genes such as LMPs, EBERs, EBV-related miRNAs 
and mRNAs, exosomes related to EBV-associated cancers may also contain other endogenous 
proteins that potentially promote cancer progression such as transcription factor Galectin-9 
[20], EGFR [30], HIF1α [19], ICAM1 [21], FGF2 [25], chemokine (C-C motif) ligand 20 (CCL20) 
[22], dUTPase [48] and interleukins (ILs)/caspase 1/interferon-inducible protein 16 (IFI16) [49] 
(Table 1).
Mrizak and co-workers demonstrated that CCL20-containing exosomes recruited the 
CD25+FOXP3+ Treg cells and enhanced their expansion in NPC [22]. The involvement of 
these exosomes in the Treg interaction may therefore support immune evasion in NPC. In the 
case of dUTPase enzyme, up-regulated expression of this enzyme has been observed in the 
exosomes derived from the EBV-positive Burkitt’s lymphoma cell line, Raji. These enzymes 
are found to induce the cytokine release from DCs and PBMCs, which may activate the NF-κB 
pathway [48].
Interestingly, exosomes derived from the Raji cells and other EBV-infected cell lines are also 
enriched with various immune modulators such as IFI16, cleaved caspase-1, IL-1β, IL-18 and 
IL-33 [49]. The presence of these proteins in these exosomes may suggest that EBV utilizes the 
host exosome pathway in immune escape of tumour hence contributing to the EBV-associated 
cancer progression.
3. Exosomes as biomarkers
We have discussed the tumorigenic role of exosomes in EBV-associated cancers in previ-
ous section. Since these exosomes carry a great variety of pathogenic molecules (Figure 2), 
they can be potentially used for diagnostic and/or prognostic markers in the EBV-related 
cancers. Indeed, several reports have highlighted the potentials of employing exosomes as 
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the biomarkers in various cancers [50, 51], and the exosome-containing miRNAs are the 
most popular cancer diagnostic markers out of all [52, 53]. There have been several lines 
of evidences suggesting that EBV oncoproteins can be targeted for cancer diagnostics. For 
instances, Houali and colleagues showed that both EBV oncoproteins, LMP1 and BARF1, 
could be detected in serum and saliva of NPC patients, and the secreted LMP1 was highly 
associated with exosome-like vesicles [54]. Both EBV oncoproteins were presented with high 
mitogenic activity that supported their implication in oncogenic development of NPC. The 
fact that exosomes are abundantly expressed in patient serum and saliva further support the 
potential of using the oncoprotein-enriched exosomes for cancer diagnostics [3–5]. Similarly, 
Mao and co-workers also highlighted the potential of LMP1 and LMP2A as the prognostic 
markers for extranodal NK/T-cell lymphoma (ENKTL) patients [55]. LMP1 and LMP2A were 
overexpressed in ENKTL tumours and they significantly correlated with the patients’ overall 
survival. However, whether or not the exosomal LMP1 and LMP2A have the similar values 
for prognosis remain to be seen.
In addition, other pathogenic factors that are enriched in EBV exosomes such as EBV DNAs, 
EBV mRNAs and EBV miRNAs have also been shown to be potential biomarkers for EBV can-
cer diagnosis [56–59] (Table 2). Using quantitative PCR (qPCR), Yip and colleagues showed 
that high-EBV DNAs could be detected in plasma/serum of NPC patients at late stages of 
disease and the viral loads were associated with poor survival or frequent relapse in NPC 
patients [56, 59]. On the other hand, Stevens and colleagues demonstrated that the EBV DNA 
load measurement might have limited value as the diagnostic marker for NPC as the viral 
load did not reflect the intact tumour cells [56, 59]. Hence, they recommended to combine 
circulating EBV DNA measurement and EBV serology to increase the diagnostic sensitiv-
ity. The same group also showed that the combination of EBV DNA and BARF1 mRNAs 
detection from patients’ nasopharyngeal brushings could be a good non-invasive method for 
Exosomal target Source/sample Cancer type Reference
LMP1 Serum, saliva, tumour Lymphoma, NPC [54, 55]
LMP2A Tumour Lymphoma [55]
BARF1 Serum, saliva NPC [54]
EBV DNAs Cell lines, tumour, NP 
brushing, serum/plasma
NPC [56, 57, 59]
EBV mRNAs Cell lines, tumour, NP 
brushing, serum
NPC [57, 59]
EBV miRNAs Cell lines, plasma NPC [58]
Galectin Tumour NPC [65]
EGFR Tumour Prostate cancer* [61]
HIF1α Tumour Breast cancer [60]
*Not EBV-associated cancer.
Table 2. Potential exosomal target for prognostic/diagnostic biomarker development in EBV cancers.
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NPC diagnosis [57]. On the other hand, Zhang and co-workers showed that EBV miRNAs 
(miR-BART7 and miR-BART13) can serve as important biomarkers for NPC diagnosis and 
prediction of treatment efficacy [58]. The potential prognostic value of EGFR and HIF1α has 
been previously demonstrated in breast and prostate cancers [60, 61]. It would be interesting 
if these proteins can also be used as prognostic markers for EBV-related cancers. However, 
this requires further investigations. While circulating EBV DNAs, mRNAs, miRNAs and 
other components in serum/plasma is useful for EBV-related cancer diagnostics, more efforts 
should be focused in discriminating the diagnostics values of cell- and exosome-derived 
nucleic acids.
More interestingly, exosomes have shown to protect their cargoes from degradation. For instance, 
it has been shown that the mRNAs and miRNAs encapsulated in exosomes are protected from 
RNAses [62]. They are more stable and can be stably employed as diagnostic biomarkers. Recent 
advances in methods have also made the exosome isolation from various biofluids simpler, 
more straightforward, and with better quality and yield [63, 64]. The EBV proteins/genes that 
can potentially be developed into diagnostic markers are summarized in Table 2.
4. Exosomes as predictive markers for therapy response
Pathogenic exosomes have been previously linked to the treatment failure of cancers [65, 66]. 
As exosomes exhibit pathogenic effects on tumour formation and progression, the oncogenic 
activity of exosomes can be intervened by blocking the production/release of the exosomes 
or the specific exosomal proteins/genes. Figure 2 summarizes the pathogenic and tumori-
genic factors derived from the EBV exosomes and the potential targets for anti-cancer ther-
apy development. In fact, there have been studies showing that EBV-associated proteins and 
nucleic acids (e.g. DNA, mRNA and miRNA) can be targeted for anti-cancer therapy develop-
ment particularly in NPC [67–70]. For instance, various strategies, such as cell-based immuno-
therapy, antibody-based and drug-based therapies, have been developed against EBV LMPs 
in NPC [68]. Similarly, Cao and colleagues also showed that DNAzyme resulted in significant 
tumour regression by targeting and cleaving off the LMP1 mRNA from NPC patients [67]. 
Other non-EBV tumour-promoting but LMP-associated proteins that could be targeted in 
NPC are EGFR [71, 72] and vascular endothelial growth factor (VEGF) [73, 74]. In addition, 
targeting the whole exosome has also been shown to be a potent therapeutic strategy for can-
cer therapy [66, 75]. However, the potential of developing these pathogenic proteins derived 
from tumour-associated exosomes into the therapy is unclear and further investigations are 
required.
As abovementioned, exosomes also contribute to the immune evasion of cancer cells [20, 22, 
23]. For example, the galectin-9-containing exosomes have been shown to inhibit the prolif-
eration and induce apoptosis of EBV-specific T cell, hence preventing the T cell-mediated 
recognition and killing of these cancer cells [20, 23]. Therefore, blocking these exosomes may 
restore the functions of immune cells to act and kill the cancer cells together with a plethora of 
other active tumour-killing activities. It can be envisioned that the development of a therapeu-
tic strategy blocking the galectin-9 or other proteins from oncogenic exosomes may restore the 
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immune surveillance. Over the past few years, considerable work has also been done on tar-
geting the whole exosomes rather than targeting the specific proteins [76, 77]. The exosomal 
removal using a modified kidney dialysis system has also been proposed to bring this thera-
peutic approach to the clinics [76]. These findings suggest that diminishing or eliminating the 
tumorigenic exosomes may be a good therapeutic approach to reverse the exosome-mediated 
cancer progression, particularly in the aspect of immune dysregulation.
5. Challenges and limitations
The facts that exosomes are ubiquitous and can be detected in most of the biofluids give 
advantages to the development of diagnostics biomarkers. Several studies have also dem-
onstrated that biologically functional and intact exosomes could be isolated from human 
plasma/serum [63, 64]. Moreover, the isolation/purification method of high-quality and quan-
tity exosomes from body fluids has greatly improved in the past few years [63, 64]. Hence, the 
development of exosome-targeting diagnostic biomarker has high potential and can be devel-
oped into an important liquid biopsy-based diagnostic test for cancers in future. However, 
several considerations need to be taken into account to ensure the success of biomarker and 
therapy development.
Sensitivity and specificity are important criteria for cancer biomarker development. While 
exosomes containing EBV-associated contents (e.g. mRNAs, miRNAs, LMPs, galectin 9 etc.) 
have tumour-promoting and pathogenic properties and are expressed during the disease 
development (Table 1), they are not specific to particular type of cancer of which they could 
contribute to such as NPC, GC, BL and so on (Figure 1). Before a specific exosomal target is 
discovered for each EBV-related cancer, other non-invasive tests such as cancer antigen screen-
ing and magnetic resonance imaging (MRI) can be carried out simultaneously to enhance the 
diagnostic outcome in terms of cancer specificity. Furthermore, the expression of some target 
protein/gene in the patients may highly depend on the disease state. The expression may be 
too low to be detected or undetected at all during the early stage of cancer, hence the sensi-
tivity may be the issue. On top of that, the quality and quantity of the pathogenic exosomes 
can be a challenge for diagnostic biomarker development even though it has been shown that 
high quality of exosomes could be detected from cancer patients [63, 64]. This will highly rely 
on the method used for the exosome isolation/purification for the diagnostic purpose, and it is 
extremely important to ensure the high consistency and reproducibility of the test.
As an important therapeutic target, EBV proteins/nucleic acids can be targeted for tumour regres-
sion as described in the previous section. Exosomes play important roles in cell-cell communica-
tion mainly by regulating cellular processes, hence complete removal of exosomes is not a feasible 
therapeutic strategy as it will affect the well-being of other normal cells or cellular processes 
under a normal condition [7, 14]. Hence, it is important to specifically target only the exosomes 
enriched with the pathogenic factors without affecting the biological activities of existing exo-
somes. In addition, the exosomal contents may largely vary and are heterogeneous depending 
on the sources or origins [7, 14]. This may be another challenge especially the targeted exosomes 
are from the patient’s body fluids that may be derived from a diverse range of cells. Furthermore, 
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some potential targets may be scarcely expressed or not at all in the targeted exosomes which 
will hinder the efficiency to target exosomes for any anti-cancer therapy. Other considerations 
include the dosage of exosome-targeting drugs that may vary from one to another, the delivery 
system for targeting exosomes, the bioavailability/stability of the delivered therapeutic molecules 
and the treatment course. Further works are required to evaluate the clinical safety of exosome-
targeting treatment strategy. Table 3 summarizes the potential challenges during the develop-
ment of diagnostic marker and therapy by targeting the exosomes in EBV cancers.
6. Conclusion
EBV-derived exosomes play seminal roles in the pathogenesis of EBV-associated cancers 
especially in NPC. Cumulative findings suggest that EBV-exosomes may be ideal targets for 
the development of diagnostic/prognostic markers and anti-cancer therapy. However, several 
issues need to be taken into account during the development as abovementioned. As limited 
studies have been carried out, more investigations are required to further validate the feasibil-
ity of targeting the pathogenic EBV exosomes for clinical diagnosis of EBV cancers. Current 
findings also suggest that the targeted exosomes could be developed into vaccines for EBV 
infections to reduce the EBV-induced cancers.
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Purpose Potential issue Note
Diagnostic biomarker development Specificity Not specific to particular cancer type
Sensitivity No/low expression in early-stage cancer
Quality Inactive and not functional exosomal content
Quantity Low yield of the pathogenic exosome or protein/gene
Anti-cancer therapy development Toxicity Off-target effect against all functional exosomes
Heterogeneity Contain multiple types of functional protein/gene
Dose and course Wide in range due to the personalized differences
Delivery Therapeutics may not reach the ubiquitous exosomes
Bioavailability Therapeutics may be degraded before reaching to the 
targets
Table 3. Potential challenges for the development of exosome-targeted cancer diagnostics and anti-cancer therapy.
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